Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Diseases

Background:

• Cardiometabolic syndrome, marked by abdominal obesity, insulin resistance, hypertension, and dyslipidemia, presents a growing global health challenge.
• Effective management is crucial for mitigating its significant impact on cardiovascular health.

Purpose of the Study:

• To review critical preventive and therapeutic strategies for cardiometabolic syndrome.
• To highlight the role of novel pharmacotherapies in managing cardiometabolic risk factors and outcomes.

Main Methods:

• Review of recent cardiovascular outcome trials and pharmacological therapies.
• Analysis of evidence for glucose-lowering medications, lipid-lowering agents, and omega-3 fatty acids.

Main Results:

• Newer glucose-lowering drugs reduce cardiovascular and renal events in type 2 diabetes mellitus (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD).
• Ezetimibe and PCSK9 inhibitors, alongside statins, manage dyslipidemia and reduce major adverse cardiovascular outcomes (MACE) in T2DM and coronary artery disease (CAD).
• Icosapent ethyl and lifestyle modifications further mitigate residual MACE risk in high-risk populations.

Conclusions:

• Novel pharmacotherapies and lifestyle interventions are essential for preventing and managing cardiometabolic syndrome.
• These strategies are vital for reducing cardiovascular and renal disease progression in T2DM and high-risk individuals.
• Integrated management approaches are key to improving cardiovascular health in the face of rising cardiometabolic disease burden.